- Page 1 and 2:
How does the operation of PHARMAC
- Page 3 and 4:
Applying the Test-Questions .......
- Page 5 and 6:
Appendix 9: Analysis of Material Re
- Page 7 and 8:
List of Abbreviations ABS Australia
- Page 9 and 10:
Attestation of Authorship I hereby
- Page 11 and 12:
I gratefully acknowledge Major Camp
- Page 13 and 14:
Abstract This thesis explores how g
- Page 15 and 16:
Chapter 1: Introduction What is thi
- Page 17 and 18:
making? Should a person’s level o
- Page 19 and 20:
there is no mathematical calculatio
- Page 21 and 22:
health, disability, treatment of ol
- Page 23 and 24:
I then moved to the subject of rati
- Page 25 and 26:
In Chapter 3, New Zealand’s past
- Page 27 and 28:
Chapter 2: Background Introduction
- Page 29 and 30:
The following journals have no auto
- Page 31 and 32:
Technological and pharmaceutical di
- Page 33 and 34:
in every sense, and attenuates the
- Page 35 and 36:
waiting time for first (or subseque
- Page 37 and 38:
Macro-Level Distributions Macro-lev
- Page 39 and 40:
(2000) in a report for the Ministry
- Page 41 and 42:
level, too many to discuss here. On
- Page 43 and 44:
effectiveness of treatment. However
- Page 45 and 46:
surgical treatment for ectopic preg
- Page 47 and 48:
In a study conducted by the Commonw
- Page 49 and 50:
They claim that health inequities c
- Page 51 and 52:
these presentations are correct, th
- Page 53 and 54:
waiting list for patient priority.
- Page 55 and 56:
care within finite resources. The c
- Page 57 and 58:
to pay for this co-operation. In 20
- Page 59 and 60:
Other results showed that 81% of th
- Page 61 and 62:
may be grounds for litigation. Henc
- Page 63 and 64: determine if decisions on the appli
- Page 65 and 66: Chapter 4: Philosophical Framework
- Page 67 and 68: extra person with a good or service
- Page 69 and 70: just actions by individuals. The th
- Page 71 and 72: among the members of the society, a
- Page 73 and 74: example of well off and powerful pe
- Page 75 and 76: necessarily much advantaged over a
- Page 77 and 78: among individuals and communities.
- Page 79 and 80: needs. This was because distinguish
- Page 81 and 82: systematic and transparent. In her
- Page 83 and 84: why PHARMAC would subsidise unecono
- Page 85 and 86: parents refusing treatment for thei
- Page 87 and 88: The first two test-questions covere
- Page 89 and 90: There was no clarity provided by th
- Page 91 and 92: good may be served by their not rec
- Page 93 and 94: Evans (2003) ranked the various typ
- Page 95 and 96: The Use of the Test-Questions in Th
- Page 97 and 98: Qualitative research methods were d
- Page 99 and 100: equirements and considerable politi
- Page 101 and 102: material and by working through the
- Page 103 and 104: and printed copies of Hansard are a
- Page 105 and 106: PHARMAC was criticised in 16 of the
- Page 107 and 108: I tried to find an interviewee from
- Page 109 and 110: The flow of discussion in the inter
- Page 111 and 112: that the disclosure is commercially
- Page 113: 6. Producing the report The final o
- Page 117 and 118: Table 3: Tree Nodes Used in NVivo A
- Page 119 and 120: At this point, I stopped using NViv
- Page 121 and 122: Chapter 6: Research Findings Introd
- Page 123 and 124: DHBs were given the role of funding
- Page 125 and 126: These measures were in response to
- Page 127 and 128: Table 5: The Submitters to the Heal
- Page 129 and 130: towards New Zealand and for them to
- Page 131 and 132: monopolies as such. In their opinio
- Page 133 and 134: for the delivery of such services (
- Page 135 and 136: NCWNZ that S42(a) of the Bill, requ
- Page 137 and 138: contentious among Maori Iwi. Any Ma
- Page 139 and 140: Dugdale further advised that if non
- Page 141 and 142: cumbersome and recommended that PHA
- Page 143 and 144: following text, I have individually
- Page 145 and 146: Herceptin. The plaintiffs forwarded
- Page 147 and 148: the treatment of cancer in the DHB
- Page 149 and 150: eligible people in New Zealand and
- Page 151 and 152: confirmation that the DHB hospital
- Page 153 and 154: the eight women involved in this ca
- Page 155 and 156: the plaintiffs adequate opportunity
- Page 157 and 158: Judge’s Concluding Remarks The fi
- Page 159 and 160: A Selection of the Media Stories Ca
- Page 161 and 162: Case 4: “Worn out by endless figh
- Page 163 and 164: Case 6: “PHARMAC scolded for MS-d
- Page 165 and 166:
The drug to treat Pompe’s Disease
- Page 167 and 168:
The Voice of Patients and Family Me
- Page 169 and 170:
Sclerosis Society did this three ti
- Page 171 and 172:
was suffering would not pass the ra
- Page 173 and 174:
Eight of the twelve persons approac
- Page 175 and 176:
Part II: The Key Informant Intervie
- Page 177 and 178:
agreed this was done. Secondly, PHA
- Page 179 and 180:
the pharmaceutical schedule. The or
- Page 181 and 182:
No we have never thought that $3 mi
- Page 183 and 184:
Insights were given as to the indep
- Page 185 and 186:
and Now some people can say that’
- Page 187 and 188:
Q Be a voice for the family? A Yes,
- Page 189 and 190:
key issue here. Some clinicians wer
- Page 191 and 192:
I deeply suspect that Community Exc
- Page 193 and 194:
should be developing the capacity o
- Page 195 and 196:
make. And so PHARMAC has been a hug
- Page 197 and 198:
and PHARMAC is not above rationing
- Page 199 and 200:
This case demonstrated that the cos
- Page 201 and 202:
and budget management. It says this
- Page 203 and 204:
Q Do you recall the Kaletra issues
- Page 205 and 206:
Q Can I ask you about PHARMAC’s c
- Page 207 and 208:
….successfully…for things espec
- Page 209 and 210:
This was also done for the hard cop
- Page 211 and 212:
The Ministry of Health could not lo
- Page 213 and 214:
consultation documents which relate
- Page 215 and 216:
The following information was recei
- Page 217 and 218:
with the application. The discharge
- Page 219 and 220:
Again no report was attached from t
- Page 221 and 222:
The patient was also prescribed pre
- Page 223 and 224:
circumstances described were not su
- Page 225 and 226:
treatment was not unusual and the c
- Page 227 and 228:
their clinical circumstances would
- Page 229 and 230:
Theme 1. Theme 2. Theme 3. Theme 4.
- Page 231 and 232:
Chapter 7: Discussion Introduction
- Page 233 and 234:
the intellectual property to recove
- Page 235 and 236:
The use of QALY’s was tested in t
- Page 237 and 238:
Test-Question 2 “Is this distribu
- Page 239 and 240:
claimants (and unsuccessful drug co
- Page 241 and 242:
(2011-2012) in an open and transpar
- Page 243 and 244:
The cost-utility analysis system ha
- Page 245 and 246:
Another form of decision making use
- Page 247 and 248:
discuss how (or if) PHARMAC meets t
- Page 249 and 250:
Test-question 4 also raises the pro
- Page 251 and 252:
when there is no profound evidence
- Page 253 and 254:
for example value for money, equity
- Page 255 and 256:
Community Exceptional Circumstances
- Page 257 and 258:
Interferon available to a limited n
- Page 259 and 260:
challenges are multiple: to identif
- Page 261 and 262:
The data from the research showed h
- Page 263 and 264:
PHARMAC could be more open about st
- Page 265 and 266:
Chapter 8: Conclusions Introduction
- Page 267 and 268:
Limitations to the Research The ite
- Page 269 and 270:
There is no one set of indefeasible
- Page 271 and 272:
to alcohol and drug treatment or th
- Page 273 and 274:
well placed to lead further researc
- Page 275 and 276:
utilitarian principles of attemptin
- Page 277 and 278:
stand up to the same rigorous clini
- Page 279 and 280:
Appendices: Appendix 1: Ethics Appr
- Page 281 and 282:
Appendix 2: Key Informant Participa
- Page 283 and 284:
Appendix 3: Key Informant Consent F
- Page 285 and 286:
Appendix 4: Sample Interview Questi
- Page 287 and 288:
Appendix 5: OIA Request Greg Coyle
- Page 289 and 290:
Appendix 6: OIA Response from PHARM
- Page 291 and 292:
Appendix 7: Community Exceptional C
- Page 293 and 294:
279
- Page 295 and 296:
281
- Page 297 and 298:
283
- Page 299 and 300:
Appendix 8: Community Exceptional C
- Page 301 and 302:
Ashton, T., & St John, S. (2008). N
- Page 303 and 304:
Cohen, G. A. (2008). Rescuing Justi
- Page 305 and 306:
Dew, K., Cumming, J., McLeod, D., M
- Page 307 and 308:
Glubb, N. (2011). Official Informat
- Page 309 and 310:
Holt, S., Harwood, M., Aldington, S
- Page 311 and 312:
Lindblom, C. E. (1959). The Science
- Page 313 and 314:
http://www.moh.govt.nz/moh.nsf/ea60
- Page 315 and 316:
Cash Flows (Ed.), Government of New
- Page 317 and 318:
PB/132 National Council of Women of
- Page 319 and 320:
Romano, C. (2009). Amartya Sen Shak
- Page 321 and 322:
Swedish Parliamentary Priorities Co